FDA Orange Book · active-ingredient family
Triamcinolone
Triamcinolone: 2 brands, 17 generics; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 17 ANDA applications approved.
Brands (NDA)
2
Generics (ANDA)
17
Listed patents
0
Presentations
27
Brand (NDA) products
Originator applications
- ASTELLASNDA 011161—5 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2MG TABLET ORAL Discontinued — 4MG TABLET ORAL Discontinued — 1MG TABLET ORAL Discontinued — 16MG TABLET ORAL Discontinued — 8MG TABLET ORAL Discontinued — - DELCOR ASSET CORPNDA 011283—4 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1MG TABLET ORAL Discontinued — 4MG TABLET ORAL Discontinued — 2MG TABLET ORAL Discontinued — 8MG TABLET ORAL Discontinued —
Generic (ANDA) products (17)
Abbreviated applications
- TRIAMCINOLONEBARRANDA 084286—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2MG TABLET ORAL Discontinued — - TRIAMCINOLONEBARRANDA 084318—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2MG TABLET ORAL Discontinued — - TRIAMCINOLONEBARRANDA 084267—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEBARRANDA 084319—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEBARRANDA 084268—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 8MG TABLET ORAL Discontinued — - TRIAMCINOLONEBARRANDA 084320—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 8MG TABLET ORAL Discontinued — - TRIAMCINOLONEIMPAX LABSANDA 084340—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEIVAX SUB TEVA PHARMSANDA 083750—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEMYLANANDA 084406—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2MG TABLET ORAL Discontinued — - TRIAMCINOLONEPUREPAC PHARMANDA 084020—2 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2MG TABLET ORAL Discontinued — 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEROXANEANDA 084708—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2MG TABLET ORAL Discontinued — - TRIAMCINOLONEROXANEANDA 084709—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEROXANEANDA 084707—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 8MG TABLET ORAL Discontinued — - TRIAMCINOLONESANDOZANDA 085601—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONETEVAANDA 084775—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEWATSON LABSANDA 084270—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued — - TRIAMCINOLONEWATSON LABSANDA 085834—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 4MG TABLET ORAL Discontinued —
Listed patents
Orange Book patent file
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Triamcinolone: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
